Best AI Medical Diagnostic Platforms - Page 2

How Many AI Medical Diagnostic Platforms Products Does G2 Track?

Total Products under this Category: 118

Category Stats (Nov 2026)

  • Average Rating: 4.4/5 (↓0.23 vs Oct 2026) The average rating of products in this category, based on all submitted ratings
  • Top Trending Product: myExam Companion (+8.75%) - Among all products in this category, myExam Companion recorded the largest rating increase compared to last month

Last updated: November 13, 2026

How Does G2 Rank AI Medical Diagnostic Platforms Products?

Why You Can Trust G2's Software Rankings:

  • 30 Analysts and Data Experts
  • 300+ Authentic Reviews
  • 118+ Products
  • Unbiased Rankings

G2's software rankings are built on verified user reviews, rigorous moderation, and a consistent research methodology maintained by a team of analysts and data experts. Each product is measured using the same transparent criteria, with no paid placement or vendor influence. While reviews reflect real user experiences, which can be subjective, they offer valuable insight into how software performs in the hands of professionals. Together, these inputs power the G2 Score, a standardized way to compare tools within every category.

G2 Grid® for AI Medical Diagnostic Platforms

G2 Grid® for AI Medical Diagnostic Platforms plotting products by satisfaction and market presence

Highlighted products: OpenEvidence, PathAI, Viz.ai One, MR SmartSpeed, 5C Network, Deep Resolve, Qure AI, and Lunit.

Underlying data: [Grid® JSON](https://www.g2.com/categories/ai-medical-diagnostic-platforms/grids.json?focus%5B%5D=openevidence&focus%5B%5D=pathai&focus%5B%5D=viz-ai-one&focus%5B%5D=mr-smartspeed&focus%5B%5D=5c-network&focus%5B%5D=deep-resolve&focus%5B%5D=qure-ai-2022-07-05&focus%5B%5D=lunit)

Bioscope.ai

Bioscope.ai is a physician-founded precision longevity platform that takes the shape of the practice it serves. Whole genomes, labs, advanced panels, imaging, microbiome tests and wearables usually arrive as separate reports. Bioscope.ai considers them as one case. As a result, doctors can see connections that wouldn't be visible one report at a time. Every finding traces to the patient's record and to the published source so the clinician can verify the evidence. Bioscope.ai runs on the doctor's philosophy of medicine. Their protocols, their thresholds and their terminology shape how each patient is seen. It flags areas to investigate, but the doctor determines the plan and presents it. Their method doesn't change. Their reach does.

Average Rating: 4.2/5.0

Total Reviews: 10

Who Is the Company Behind Bioscope.ai?

  • Seller: Bioscope.ai
  • Company Website:
  • Year Founded: 2025
  • HQ Location: Carmel, US
  • LinkedIn® Page: www.linkedin.com
    53 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 70% Small, 40% Medium

What Are Recent G2 Reviews of Bioscope.ai?

Chest X-ray Reporting

qXR is an advanced AI-powered solution designed to enhance the efficiency and accuracy of chest X-ray interpretation. Trained on over 9 million scans and having processed more than 10.7 million, qXR delivers comprehensive reports in under 20 seconds, significantly reducing turnaround times by 40%. It identifies a wide range of abnormalities across the lungs, pleura, mediastinum, bones, diaphragm, and heart, aiding in the detection of conditions such as tuberculosis and lung cancer. With a 99% negative predictive value in segregating unremarkable chest X-rays, qXR effectively clears reporting backlogs and supports high-volume settings like teleradiology and immigration screenings. Its multilingual support and flexible deployment options, including cloud and on-premise, ensure seamless integration into diverse clinical environments.

Average Rating: 4.4/5.0

Total Reviews: 7

Who Is the Company Behind Chest X-ray Reporting?

  • Seller: Qure.ai
  • Year Founded: 2016
  • HQ Location: New York , US
  • LinkedIn® Page: www.linkedin.com
    426 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 71% Small, 43% Medium

What Are Recent G2 Reviews of Chest X-ray Reporting?

VUNO Med-DeepBrain

VUNO Med-DeepBrain is an AI-powered medical device designed to assist in the diagnosis of neurodegenerative diseases by analyzing brain MRI scans. It automates the segmentation and quantification of over 100 brain regions, providing detailed volumetric data, cortical thickness measurements, and white matter hyperintensity assessments. By comparing a patient's brain atrophy data to a normative population, the software generates a comprehensive report with statistical analyses, visual graphs, and diagrams, aiding clinicians in identifying conditions such as Alzheimer's disease and vascular dementia. Key Features and Functionality: - Automated Brain Segmentation: Utilizes deep learning algorithms to divide brain MRI images into more than 100 distinct regions, facilitating precise analysis. - Quantitative Analysis: Provides volumetric measurements, cortical thickness data, and white matter hyperintensity evaluations for each segmented region. - Normative Comparison: Compares individual patient data against age- and gender-matched normative datasets, offering percentile scores to highlight deviations from typical brain structures. - Comprehensive Reporting: Generates customizable reports featuring statistical results, visual graphs, and color-coded overlays to enhance diagnostic interpretation. - Regulatory Approvals: Certified by the U.S. FDA, CE, and MFDS (K-FDA), ensuring compliance with international medical device standards. Primary Value and User Benefits: VUNO Med-DeepBrain streamlines the traditionally manual and time-consuming process of brain MRI analysis, enabling rapid and accurate assessment of neurodegenerative conditions. By providing objective, quantifiable data, it enhances diagnostic precision, supports early detection of diseases like Alzheimer's, and facilitates monitoring of disease progression. This efficiency not only improves patient outcomes through timely intervention but also optimizes clinical workflows, allowing healthcare professionals to allocate more time to patient care.

Average Rating: 4.9/5.0

Total Reviews: 5

Who Is the Company Behind VUNO Med-DeepBrain?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 60% Medium, 20% Small

What Are Recent G2 Reviews of VUNO Med-DeepBrain?

AI can help you find the answers. G2 helps you trust them.

Connect G2 to Claude or ChatGPT for answers grounded in G2's trusted reviews, comparisons, and pricing from real user insights.

How it works

Arterys MICA

Arterys MICA is a medical imaging software for image analytics that can assist with cardio, lung, and liver diagNoses.

Average Rating: 4.0/5.0

Total Reviews: 4

Who Is the Company Behind Arterys MICA?

  • Seller: Arterys
  • Year Founded: 2013
  • HQ Location: San Francisco, US
  • LinkedIn® Page: www.linkedin.com
    16 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 60% Medium, 40% Small

What Are Recent G2 Reviews of Arterys MICA?

Stroke & TBI

qER by Qure.ai is an AI-powered solution designed to enhance the diagnosis and management of stroke and traumatic brain injury (TBI) through rapid and accurate analysis of non-contrast head CT scans. By integrating seamlessly into existing radiology workflows, qER prioritizes critical cases, enabling faster team activation and improved patient outcomes. The system detects and quantifies key abnormalities such as intracranial hemorrhages, cranial fractures, mass effect, and midline shifts, providing clinicians with comprehensive insights to make informed decisions promptly. With regulatory clearances including FDA 510(k) and CE Class IIb certifications, qER is a trusted tool in neuro-critical care settings.

Average Rating: 4.7/5.0

Total Reviews: 5

Who Is the Company Behind Stroke & TBI?

  • Seller: Qure.ai
  • Year Founded: 2016
  • HQ Location: New York , US
  • LinkedIn® Page: www.linkedin.com
    426 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 60% Small, 40% Medium

What Are Recent G2 Reviews of Stroke & TBI?

qER

From medical images to connected devices, the amount of medical data being generated is growing exponentially. This coupled with new forms of data such as the ones generated by genome sequencing and biosensors renders traditional diagnostic methods obsolete. At Qure, we are a team of passionate computer scientists, medical practitioners and bioinformaticians who are on a mission to make healthcare more accessible and affordable using the power of deep learning.

Average Rating: 4.7/5.0

Total Reviews: 3

Who Is the Company Behind qER?

  • Seller: Qure.ai
  • Year Founded: 2016
  • HQ Location: New York , US
  • LinkedIn® Page: www.linkedin.com
    426 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 33% Large, 33% Medium

What Are Recent G2 Reviews of qER?

VUNO Med-BoneAge

VUNO Med®-BoneAge™ is an AI-powered diagnostic tool designed to assist healthcare professionals in assessing bone age through the analysis of hand X-ray images. By leveraging deep learning algorithms, it automatically evaluates the X-ray and presents the three most probable bone age candidates, streamlining the diagnostic process and enhancing accuracy. This solution is particularly beneficial in diagnosing growth disorders, such as short stature, tall stature, early or late puberty, and congenital adrenal hyperplasia, by providing precise bone age assessments. Key Features and Functionality: - Automated Bone Age Assessment: Utilizes AI to analyze hand X-ray images, delivering the top three most likely bone age results based on the Greulich-Pyle (GP) method, which categorizes males into 31 groups and females into 27 groups. - Efficient Workflow Integration: Reduces the time required for bone age evaluation by eliminating the need for manual comparison with reference materials. Clinicians can quickly select the most appropriate age from the provided options, enhancing workflow efficiency. - Comprehensive Reporting: Generates detailed reports that include visual graphs projecting the patient's final height, considering factors such as current age, height, and gender. This facilitates clear communication between healthcare providers and patients, improving patient engagement and satisfaction. - Regulatory Approvals: Recognized as Korea's first AI medical device, VUNO Med-BoneAge has received approvals from the Korean Ministry of Food and Drug Safety (MFDS) and the European CE certification, ensuring compliance with international medical standards. Primary Value and User Benefits: VUNO Med-BoneAge addresses the challenges associated with traditional bone age assessment methods, which can be time-consuming and subject to variability among clinicians. By automating the evaluation process, it significantly reduces reading time and enhances the consistency and accuracy of assessments. This leads to more reliable diagnoses of growth-related conditions, enabling timely and appropriate interventions. Additionally, the user-friendly interface and comprehensive reporting support effective communication with patients, fostering better understanding and adherence to treatment plans.

Average Rating: 4.3/5.0

Total Reviews: 3

Who Is the Company Behind VUNO Med-BoneAge?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 33% Large, 33% Medium

What Are Recent G2 Reviews of VUNO Med-BoneAge?

Enlitic

A machine learning solution for diagnostic healthcare.

Average Rating: 4.0/5.0

Total Reviews: 5

Who Is the Company Behind Enlitic?

  • Seller: Enlitic
  • Year Founded: 2014
  • HQ Location: Fort Collins, US
  • LinkedIn® Page: www.linkedin.com
    45 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 83% Small, 17% Medium

What Are Recent G2 Reviews of Enlitic?

Lung Nodule Management

Qure.ai's Lung Nodule Management suite is an AI-driven solution designed to enhance the early detection and management of lung nodules, thereby facilitating prompt intervention and improving patient outcomes. This comprehensive suite integrates advanced algorithms to analyze chest X-rays and CT scans, providing clinicians with rapid, accurate, and detailed assessments of lung health.

Average Rating: 4.3/5.0

Total Reviews: 2

Who Is the Company Behind Lung Nodule Management?

  • Seller: Qure.ai
  • Year Founded: 2016
  • HQ Location: New York , US
  • LinkedIn® Page: www.linkedin.com
    426 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 50% Large, 50% Small

What Are Recent G2 Reviews of Lung Nodule Management?

VUNO Med-Chest X-ray

VUNO Med®-Chest X-ray™ is an AI-powered diagnostic support solution designed to assist healthcare professionals in interpreting chest X-ray images. By analyzing key thoracic abnormalities, it enhances the detection and diagnosis of major lung diseases such as lung cancer, tuberculosis, and pneumonia. Key Features and Functionality: - Detection of Major Abnormalities: The system identifies five critical thoracic findings: nodule/mass, consolidation, interstitial opacity, pneumothorax, and pleural effusion. - Intuitive User Interface: Provides clear visualizations, including abnormality scores and lesion heatmaps, to aid in clinical decision-making. - Seamless Integration: Compatible with Picture Archiving and Communication Systems (PACS) and offers cloud-based services for flexible deployment. - Rapid Analysis: Delivers results in under 10 seconds, facilitating prompt clinical responses. - Regulatory Approvals: Certified by the Korea Ministry of Food and Drug Safety (MFDS) and holds CE certification, ensuring compliance with international medical device standards. Primary Value and User Benefits: VUNO Med®-Chest X-ray™ streamlines the diagnostic process by providing immediate, accurate analysis of chest X-rays, thereby reducing reading times and improving diagnostic accuracy. This efficiency supports healthcare providers in delivering timely and precise patient care, particularly in detecting and managing critical lung conditions.

Average Rating: 4.8/5.0

Total Reviews: 2

Who Is the Company Behind VUNO Med-Chest X-ray?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 50% Medium, 50% Small

What Are Recent G2 Reviews of VUNO Med-Chest X-ray?

VUNO Med-DeepCARS

VUNO Med®-DeepCARS® is an AI-powered medical device designed to predict the risk of in-hospital cardiac arrest within the next 24 hours for patients in general wards. By continuously analyzing vital signs—including blood pressure, heart rate, respiratory rate, and body temperature—DeepCARS® provides a risk score ranging from 0 to 100, enabling healthcare professionals to monitor patients effectively and manage risks proactively. Key Features and Functionality: - Simplicity: Utilizes only four vital signs to generate a cardiac arrest risk score, facilitating straightforward integration into existing clinical workflows. - Effectiveness: Demonstrated high predictive accuracy in multicenter studies, with an area under the receiver operating characteristic curve (AUROC) of 0.860 in internal validation and 0.905 in external validation. - Efficiency: On average, provides a 15.8-hour lead time from the first prediction to the actual occurrence of cardiac arrest, allowing for timely clinical interventions. Primary Value and User Benefits: DeepCARS® addresses the critical need for early detection of potential cardiac arrests in hospitalized patients. By offering timely and accurate risk assessments, it empowers healthcare providers to intervene proactively, thereby enhancing patient safety and improving clinical outcomes. Its simplicity and efficiency make it a valuable tool in general wards, supporting medical staff in delivering prompt and effective care.

Average Rating: 4.8/5.0

Total Reviews: 2

Who Is the Company Behind VUNO Med-DeepCARS?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 100% Small

What Are Recent G2 Reviews of VUNO Med-DeepCARS?

VUNO Med-Fundus AI

VUNO Med-Fundus AI is an advanced AI-powered diagnostic support solution designed to analyze retinal fundus images, aiding in the detection and diagnosis of various retinal diseases. By leveraging deep learning algorithms trained on a vast dataset of over 100,000 fundus images, this tool provides rapid and accurate identification of critical abnormalities, enhancing the efficiency and accuracy of ophthalmic assessments. Key Features and Functionality: - Detection of 12 Abnormalities: The system identifies and locates twelve essential retinal abnormalities, including drusen, hemorrhage, hard exudate, cotton wool patch, vascular abnormality, glaucomatous disc change, retinal nerve fiber layer defect, membrane, chorioretinal atrophy, non-glaucomatous disc change, macular hole, and myelinated nerve fiber. - Automated Region Mapping: It automatically detects the optic disc and macula, segmenting the fundus into eight regions—macular, superior optic disc, inferior optic disc, temporal, superotemporal, inferotemporal, superonasal, and inferonasal—to assist in precise localization of detected abnormalities. - Comprehensive Patient Reports: The software generates detailed reports that visualize detected anomalies, facilitating clear communication between healthcare providers and patients. Primary Value and User Benefits: VUNO Med-Fundus AI significantly enhances the diagnostic workflow for ophthalmologists by providing swift and accurate detection of retinal abnormalities. This leads to earlier identification of conditions such as diabetic retinopathy, macular degeneration, and glaucoma, which are critical for preventing vision loss. The system's efficiency reduces the time required for image analysis, allowing clinicians to focus more on patient care. Additionally, the clear visualization of findings improves patient understanding and engagement in their treatment plans.

Average Rating: 4.3/5.0

Total Reviews: 2

Who Is the Company Behind VUNO Med-Fundus AI?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 100% Small

What Are Recent G2 Reviews of VUNO Med-Fundus AI?

VUNO Med-LungCT AI

VUNO Med®-LungCT AI™ is an advanced artificial intelligence solution designed to assist healthcare professionals in the detection and analysis of pulmonary nodules from chest CT scans. By leveraging cutting-edge AI algorithms, it enhances the accuracy and efficiency of lung disease diagnoses, providing critical data on nodule size, volume, and location. Key Features and Functionality: - Nodule Detection and Quantification: Identifies pulmonary nodules within chest CT images, offering precise measurements of their size and volume. - Comprehensive Nodule Information: Provides detailed data on nodule type, location, calcification, and spiculation, facilitating thorough assessments. - Lung-RADS Categorization: Automatically classifies nodules according to the Lung-RADS system, aiding in standardized reporting and management. - Longitudinal Tracking: Enables comparison of serial CT scans by matching baseline and follow-up images, assisting in monitoring nodule growth over time. - Integration with PACS: Seamlessly integrates results into Picture Archiving and Communication Systems (PACS) using GSPS objects, ensuring user convenience and streamlined workflow. Primary Value and User Benefits: VUNO Med®-LungCT AI™ addresses the critical need for early detection of lung diseases, particularly lung cancer, by providing rapid and accurate analysis of chest CT scans. Its high sensitivity and low false-positive rate reduce the likelihood of missed diagnoses, thereby improving patient outcomes. The solution's ability to deliver detailed nodule information and standardized categorization enhances diagnostic confidence and supports effective patient management. By integrating seamlessly into existing medical imaging workflows, it minimizes additional workload for radiologists, allowing for more efficient and accurate assessments.

Average Rating: 4.8/5.0

Total Reviews: 2

Who Is the Company Behind VUNO Med-LungCT AI?

  • Seller: Vuno
  • Year Founded: 2014
  • HQ Location: Seoul, KR
  • LinkedIn® Page: www.linkedin.com
    100 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 100% Medium

What Are Recent G2 Reviews of VUNO Med-LungCT AI?

Denti.AI

Denti.AI is an innovative artificial intelligence company dedicated to transforming dental care through AI-powered solutions. Since its inception in 2018, Denti.AI has focused on enhancing patient care, streamlining dental workflows, and improving diagnostic accuracy. By integrating advanced AI technologies, Denti.AI offers a suite of products designed to automate and optimize various aspects of dental practice, allowing professionals to concentrate more on patient interactions and less on administrative tasks. Key Features and Functionality: - Denti.AI Scribe: An AI-powered assistant that records clinician-patient conversations, providing real-time transcription and generating customizable clinical notes. This tool supports over 20 languages and ensures secure, HIPAA-compliant documentation. - Denti.AI Voice Perio: A voice-activated periodontal charting solution enabling hygienists to complete charts in approximately five minutes without the need for an assistant. It enhances time efficiency, ergonomics, and infection control. - Denti.AI Detect: An FDA-cleared imaging solution that aids in identifying dental diseases such as caries, periapical lesions, and bone loss from x-rays. Clinical studies have shown a 26% increase in treatment opportunities with its use. - Denti.AI Auto-Chart: A patented AI solution that automates the charting of restorations, root canals, implants, crowns, and missing teeth, reducing manual clicks by 70% and integrating seamlessly with Practice Management Systems (PMS). Primary Value and Solutions Provided: Denti.AI addresses several critical challenges in dental practices: - Time Efficiency: By automating documentation and charting processes, Denti.AI's solutions save dental professionals 1-2 hours daily, allowing more time for patient care. - Diagnostic Accuracy: The AI-driven tools enhance the detection of dental pathologies, leading to earlier diagnoses and improved patient outcomes. - Operational Efficiency: Seamless integration with existing PMS and imaging systems streamlines workflows, reducing manual tasks and minimizing errors. - Patient Education: Auto-generated, easy-to-understand reports improve patient comprehension of their oral health, boosting case acceptance rates. By leveraging Denti.AI's comprehensive suite of AI-powered tools, dental practices can enhance efficiency, accuracy, and patient satisfaction, ultimately leading to better overall dental care.

Average Rating: 4.0/5.0

Total Reviews: 1

Who Is the Company Behind Denti.AI?

  • Seller: Denti.AI
  • Year Founded: 2018
  • HQ Location: Dover, US
  • LinkedIn® Page: www.linkedin.com
    53 employees on LinkedIn®

Who Uses This Product?

  • Company Size: 100% Small

What Are Recent G2 Reviews of Denti.AI?

0Xmd

0xmd is a pioneering technology company specializing in Generative Artificial Intelligence (AI) solutions tailored for the healthcare sector. With operations in Hong Kong, the United States, and China, 0xmd is dedicated to transforming healthcare by enhancing diagnostic accuracy, improving patient care, and optimizing medical systems. Their mission is to make healthcare resources more equitable and accessible through innovative AI-driven solutions. Key Features and Functionality: - AI Health Assistant: Developed large language models (LLMs) specifically for medical and health applications, providing personalized medical and health information to users. - Advanced Image Analysis: - Food & Medicine Scanner: Utilizes AI to instantly identify ingredients, nutritional content, and medication details, aiding users in making informed health decisions. - Physical Examination Report Scanner: Employs advanced visual AI tools to read and analyze physical examination reports, offering key insights and related health information. - Dermatological Detection: Applies medical visual AI to detect skin diseases, providing critical insights and relevant medical information. - AI X-ray Examination: Features a deep learning model that assists in analyzing X-ray images to identify diseases. Primary Value and Solutions: 0xmd addresses critical challenges in the healthcare industry by leveraging AI to enhance diagnostic precision, reduce misdiagnosis rates, and support medical professionals in delivering personalized and efficient care. Their solutions improve accessibility to quality healthcare information, especially for underserved communities and remote areas, thereby promoting health equity. By integrating advanced AI technologies, 0xmd empowers healthcare providers and patients to make informed decisions, ultimately leading to better health outcomes and a more efficient healthcare ecosystem.

Who Is the Company Behind 0Xmd?

Emma Stein
ES
Researched and written by Emma Stein
Updated October 21, 2026